Glad the formula only is working again.
Carrageenan is a high molecular weight sulfated polygalactan used to improve the texture of commercial food products. Its use increased markedly during the last half century, although carrageenan is known to induce inflammation in rheumatological models and in intestinal models of colitis. We performed studies to determine its direct effects on human intestinal cells, including normal human intestinal epithelial cells from colonic surgeries, the normal intestinal epithelial cell line NCM460, and normal rat ileal epithelial cells. Cells were treated with high molecular weight λ-carrageenan at a concentration of 1 μg/ml for 1–96 h. IL-8, IL-8 promoter activity, total and nuclear NF-κB, IκBα, phospho-IκBα, and Bcl10 were assessed by immunohistochemistry, Western blot, ELISA, and cDNA microarray. Increased Bcl10, nuclear and cytoplasmic NF-κB, IL-8 promoter activation, and IL-8 secretion were detected following carrageenan exposure. Knockdown of Bcl10 by siRNA markedly reduced the increase in IL-8 that followed carrageenan exposure in the NCM460 cells. These results show, for the first time, that exposure of human intestinal epithelial cells to carrageenan triggers a distinct inflammatory pathway via activation of Bcl10 with NF-κB activation and upregulation of IL-8 secretion. Since Bcl10 contains a caspase-recruitment domain, similar to that found in NOD2/CARD15 and associated with genetic predisposition to Crohn's disease, the study findings may represent a link between genetic and environmental etiologies of inflammatory bowel disease. Because of the high use of carrageenan as a food additive in the diet, the findings may have clinical significance
Abstract
In this article I review the association between exposure to carrageenan and the occurrence of colonic ulcerations and gastrointestinal neoplasms in animal models. Although the International Agency for Research on Cancer in 1982 identified sufficient evidence for the carcinogenicity of degraded carrageenan in animals to regard it as posing a carcinogenic risk to humans, carrageenan is still used widely as a thickener, stabilizer, and texturizer in a variety of processed foods prevalent in the Western diet. I reviewed experimental data pertaining to carrageenan's effects with particular attention to the occurrence of ulcerations and neoplasms in association with exposure to carrageenan. In addition, I reviewed from established sources mechanisms for production of degraded carrageenan from undegraded or native carrageenan and data with regard to carrageenan intake. Review of these data demonstrated that exposure to undegraded as well as to degraded carrageenan was associated with the occurrence of intestinal ulcerations and neoplasms. This association may be attributed to contamination of undegraded carrageenan by components of low molecular weight, spontaneous metabolism of undegraded carrageenan by acid hydrolysis under conditions of normal digestion, or the interactions with intestinal bacteria. Although in 1972, the U.S. Food and Drug Administration considered restricting dietary carrageenan to an average molecular weight > 100,000, this resolution did not prevail, and no subsequent regulation has restricted use. Because of the acknowledged carcinogenic properties of degraded carrageenan in animal models and the cancer-promoting effects of undegraded carrageenan in experimental models, the widespread use of carrageenan in the Western diet should be reconsidered.
Carageenans are a group of high molecular weight sulphated polygalactans which find extensive use in the food industry as thickening, gelling and protein‐suspending agents. Although there is no evidence to suggest that the persorption of small amounts of carageenans across the intestinal barrier poses an acute toxic hazard, they are known to be biologically active in a number of physiological systems and extended oral administration in laboratory animals has been shown to modify both in vivo and in vitro immune competence. Whereas this effect could be attributed to carrageenan having a selective toxic effect on antigen‐processing macrophages, additional studies suggest that macrophages can also influence immune responses by the timed release of immunoregulatory mediators. Evidence in support of this comes from in vitro studies which demonstrate that carrageenan‐treated macrophages can, depending on conditions and time of administration, release either stimulatory or inhibitory factors. The former is known to be the immunostimulatory agent interleukin 1 (IL‐1). The inhibitory factor, which is produced at an early stage following exposure to non‐toxic doses of carrageenans, has yet to be formally identified but it is believed to be a prostaglandin because of its specific mode of action and short biological half‐life.
At present it is impossible to relate these studies to the human situation. Although it is established that carrageenans can cross the intestinal barrier of experimental animals, there is no evidence to suggest that the limited uptake that may occur in man in any way interferes with normal immune competence. Nevertheless, increased exposure may occur in the neonate during weaning, and adults and children following allergic reactions and episodes of gastrointestinal disease. Further studies under such conditions now seem warranted in order to elucidate the possible immunological consequences which may be associated with enhanced uptake of carrageenans in vulnerable groups.
Rodent models are increasingly utilized to investigate management and treatment of inflammatory bowel disease and reduction in the heightened risk of colon cancer. Among various agents which induce inflammation in the colons of animals, is the degraded form of Carrageenan. Degraded Carrageenan is highly toxic and also carcinogenic. Recently, undegraded Carrageenan has been found to increase the risk of colon cancer and induce a number of cytokines and enzymes known to be involved in inflammation. Undegraded Carrageenan is non-carcinogenic and when administered in the diet of the animals induce sustained inflammation without bleeding and ulceration. Therefore, undegraded Carrageenan may serve to be a superior agent to use to induce inflammatory responses in a long term animal studies. Recent advances in MRS technology to assess cellular changes in a small tissue sample may provide a sensitive approach to investigate the presence or absence of inflammation. The main objective of the present study was to determine if 2 or 4% Carrageenan in the diet would elicit responses in the colon within a short time
Multiple studies in animal models have shown that the commonly used food additive carrageenan (CGN) induces inflammation and intestinal neoplasia. We performed the first studies to determine the effects of CGN exposure on human intestinal epithelial cells (IEC) in tissue culture and tested the effect of very low concentrations (1–10 mg/L) of undegraded, high-molecular weight CGN. These concentrations of CGN are less than the anticipated exposure of the human colon to CGN from the average Western diet. In the human colonic epithelial cell line NCM460 and in primary human colonic epithelial cells that were exposed to CGN for 1–8 d, we found increased cell death, reduced cell proliferation, and cell cycle arrest compared with unexposed control cells. After 6–8 d of CGN exposure, the percentage of cells reentering G0-G1 significantly decreased and the percentages of cells in S and G2-M phases significantly increased. Increases in activated p53, p21, and p15 followed CGN exposure, consistent with CGN-induced cell cycle arrest. Additional data, including DNA ladder, poly ADP ribose polymerase Western blot, nuclear DNA staining, and activities of caspases 3 and 7, indicated no evidence of increased apoptosis following CGN exposure and were consistent with CGN-induced necrotic cell death. These data document for the first time, to our knowledge, marked adverse effects of low concentrations of CGN on survival of normal human IEC and suggest that CGN exposure may have a role in development of human intestinal pathology.
Update: Son inserted his NG tube by himself, first try - woo hoo! Did great on his first feed. We didn't get to the 1000 ml, as we are stair-stepping him up... he did about 600 ml and about 900 calories. Did great, although he did throw up this morning, so tonight, I'll keep him at the same volume, just keep the pump going at 60 ml/hr for 10 hours and not starting at 20, then increasing every 2 hours by 20 ...
Question: I don't see any lubricant packs in my supplies. I'm goig to ask the home health company on monday but can I get those little packs somewhere? I read that you cannot use vaseline as it destroys the integrity of the tube.
thanks!
Update: Son inserted his NG tube by himself, first try - woo hoo! Did great on his first feed. We didn't get to the 1000 ml, as we are stair-stepping him up... he did about 600 ml and about 900 calories. Did great, although he did throw up this morning, so tonight, I'll keep him at the same volume, just keep the pump going at 60 ml/hr for 10 hours and not starting at 20, then increasing every 2 hours by 20 ...
Question: I don't see any lubricant packs in my supplies. I'm goig to ask the home health company on monday but can I get those little packs somewhere? I read that you cannot use vaseline as it destroys the integrity of the tube.
thanks!
Update on Jaedyn...she is done with EEN. She started with a fecal calprotectin of 632 and ended with a level of 93. I'm pretty happy with that, but would have loved to see it less than 50! She started with 70 lbs and ended after 8 weeks at 75 lbs. She had a couple of colds and the stomach flu during her course, which I think slowed down the weight gain she might have otherwise had - and was intolerant to the Ensure she drank for the first 3 weeks...
Fabulous! Is she enjoying food like never before?
Is anyone using PEDIASURE EN or any other Abbot Lab product for EN or supplementing?? If you are giving this to your Crohnie, PLEASE STOP. These products contain a known GI inflammatory ingredient: CARRAGEENAN which I believed has made my son VERY ill. He just had a 2 foot jejunal resection.
when I went to test the pH of the stomach contents, nothing came up through the syringe.. we may not end up doing this tonight. Waiting half hour and will test again, but if nothing comes up into the syringe, I'm removing the tube and starting again tomorrow night..not going to insert a new tube tonight